Given the availability and potential therapeutic effects of EZH2 inhibitors and the dire need for new OS treatment options, we conducted preclinical studies to explore the potential therapeutic benefit of EZH2 inhibition on osteosarcoma progression and the development/suppression of pulmonary metastatic disease . This evidence concerns the gene EZH2 and metastatic neoplasm.